The global dyslipidemia drugs market size was estimated to be USD 18.29 billion in 2023 and is expected to reach USD 30.98 billion by 2034 with a CAGR of 4.91% during the forecast period 2024-2034. Rising prevalence of dyslipidemia, growing cardiovascular disease burden, increasing awareness and screening, advancements in drug development, government initiatives for cardiovascular health, and expanding geriatric population will drive the market growth,
Millions of people worldwide suffer from dyslipidemia, which is defined by elevated levels of triglycerides and cholesterol. According to WHO estimates, one in three persons have high levels of low-density lipoprotein (LDL, or "bad") cholesterol. One of the main risk factors for cardiovascular diseases (CVDs), the world's leading cause of mortality, is dyslipidemia. This correlation greatly increases the demand for efficient cholesterol-lowering drugs. For instance, in December 2023, Pfizer Inc. introduced Inclusa (inclisiran), the first siRNA treatment for decreasing cholesterol.
By drug class, the statins segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the well-established efficacy and widespread utilization of statin medications, their proven ability to lower cholesterol levels and reduce cardiovascular risk, consistent physician preference, and continuous patient adoption, supported by a robust body of clinical evidence endorsing their effectiveness in managing dyslipidemia. For instance, in September 2023, AstraZeneca plc presented encouraging Phase 3 findings from the MEDSCAPE-2B trial, which used Solibris (bimekizumab) to treat mixed dyslipidemia and ASCVD. Additionally, the PCSK9 inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their potent cholesterol-lowering capabilities, the demand for novel and targeted approaches in dyslipidemia management, advancements in biopharmaceutical technology facilitating the development of these innovative drugs, and a growing patient population seeking alternative therapeutic options for better lipid control and cardiovascular risk reduction.
By indication, the hypercholesterolemia segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the prevalence of elevated cholesterol levels worldwide, the increasing awareness and diagnosis of hypercholesterolemia as a significant cardiovascular risk factor, a growing patient pool seeking pharmacological interventions, and the widespread prescription of lipid-lowering medications. For instance, in December 2023, the primary goal of Amgen Inc.'s Phase 3 HARMONY trial for familial chylomicronemia syndrome with AMG 890 was fulfilled. Additionally, the mixed dyslipidemia segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of its complex nature involving elevated levels of both cholesterol and triglycerides, an increased focus on comprehensive lipid management strategies, advancements in drug development targeting mixed dyslipidemia specifically, and rising patient demand for tailored therapeutic interventions addressing the multifaceted aspects of lipid disorders for improved cardiovascular risk reduction.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the widespread accessibility and convenience offered by retail outlets, the increasing trend of self-management and prescription fulfillment at community pharmacies, and a growing patient preference for obtaining dyslipidemia medications through easily accessible retail channels, fostering better adherence and continuity of care. For instance, in December 2023, Eli Lilly and Company announced a partnership with Bayer to research and market novel treatments for cardiovascular disorders, including dyslipidemia. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating adoption of e-commerce and digital healthcare platforms, increased consumer convenience in procuring medications from the comfort of their homes, the growing trend of telemedicine, and advancements in secure online transactions and prescription verification, facilitating a shift towards the digital distribution of dyslipidemia drugs.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of dyslipidemia in the population, strong emphasis on cardiovascular health, extensive research and development activities, widespread adoption of advanced medical technologies, and robust healthcare policies, which collectively contribute to a significant demand for dyslipidemia drugs in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of dyslipidemia and cardiovascular health, rising incidence of lifestyle-related risk factors, expanding healthcare infrastructure, growing healthcare expenditures, and a burgeoning population with changing dietary habits and sedentary lifestyles, all of which contribute to a heightened demand for dyslipidemia drugs in the region. For instance, in June 2023, the Bristol Myers Squibb Company and Akcea Therapeutics entered into a commercial agreement for the commercialization of VOLTADOL (colesevelam acetate) for the treatment of familial hypercholesterolemia.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Millions of people worldwide suffer from dyslipidemia, which is defined by elevated levels of triglycerides and cholesterol. According to WHO estimates, one in three persons have high levels of low-density lipoprotein (LDL, or "bad") cholesterol. One of the main risk factors for cardiovascular diseases (CVDs), the world's leading cause of mortality, is dyslipidemia. This correlation greatly increases the demand for efficient cholesterol-lowering drugs. For instance, in December 2023, Pfizer Inc. introduced Inclusa (inclisiran), the first siRNA treatment for decreasing cholesterol.
By drug class, the statins segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the well-established efficacy and widespread utilization of statin medications, their proven ability to lower cholesterol levels and reduce cardiovascular risk, consistent physician preference, and continuous patient adoption, supported by a robust body of clinical evidence endorsing their effectiveness in managing dyslipidemia. For instance, in September 2023, AstraZeneca plc presented encouraging Phase 3 findings from the MEDSCAPE-2B trial, which used Solibris (bimekizumab) to treat mixed dyslipidemia and ASCVD. Additionally, the PCSK9 inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their potent cholesterol-lowering capabilities, the demand for novel and targeted approaches in dyslipidemia management, advancements in biopharmaceutical technology facilitating the development of these innovative drugs, and a growing patient population seeking alternative therapeutic options for better lipid control and cardiovascular risk reduction.
By indication, the hypercholesterolemia segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the prevalence of elevated cholesterol levels worldwide, the increasing awareness and diagnosis of hypercholesterolemia as a significant cardiovascular risk factor, a growing patient pool seeking pharmacological interventions, and the widespread prescription of lipid-lowering medications. For instance, in December 2023, the primary goal of Amgen Inc.'s Phase 3 HARMONY trial for familial chylomicronemia syndrome with AMG 890 was fulfilled. Additionally, the mixed dyslipidemia segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of its complex nature involving elevated levels of both cholesterol and triglycerides, an increased focus on comprehensive lipid management strategies, advancements in drug development targeting mixed dyslipidemia specifically, and rising patient demand for tailored therapeutic interventions addressing the multifaceted aspects of lipid disorders for improved cardiovascular risk reduction.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the widespread accessibility and convenience offered by retail outlets, the increasing trend of self-management and prescription fulfillment at community pharmacies, and a growing patient preference for obtaining dyslipidemia medications through easily accessible retail channels, fostering better adherence and continuity of care. For instance, in December 2023, Eli Lilly and Company announced a partnership with Bayer to research and market novel treatments for cardiovascular disorders, including dyslipidemia. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating adoption of e-commerce and digital healthcare platforms, increased consumer convenience in procuring medications from the comfort of their homes, the growing trend of telemedicine, and advancements in secure online transactions and prescription verification, facilitating a shift towards the digital distribution of dyslipidemia drugs.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of dyslipidemia in the population, strong emphasis on cardiovascular health, extensive research and development activities, widespread adoption of advanced medical technologies, and robust healthcare policies, which collectively contribute to a significant demand for dyslipidemia drugs in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of dyslipidemia and cardiovascular health, rising incidence of lifestyle-related risk factors, expanding healthcare infrastructure, growing healthcare expenditures, and a burgeoning population with changing dietary habits and sedentary lifestyles, all of which contribute to a heightened demand for dyslipidemia drugs in the region. For instance, in June 2023, the Bristol Myers Squibb Company and Akcea Therapeutics entered into a commercial agreement for the commercialization of VOLTADOL (colesevelam acetate) for the treatment of familial hypercholesterolemia.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Indication, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Dyslipidemia Drugs Market Report 2023 - 2034
Dyslipidemia Drugs Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Statins
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
- Bile Acid Sequestrants
- Fibric Acid Derivatives
- Niacin
- Others
Dyslipidemia Drugs Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Hypercholesterolemia
- Mixed Dyslipidemia
- Hypertriglyceridemia
- Others
Dyslipidemia Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Retail pharmacy
- Online Pharmacy
Dyslipidemia Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Dyslipidemia Drugs Market: Drug Class Estimates & Trend Analysis
8. Dyslipidemia Drugs Market: Indication Estimates & Trend Analysis
9. Dyslipidemia Drugs Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Dyslipidemia Drugs Market
12. Europe Global Dyslipidemia Drugs Market
13. Asia Pacific Global Dyslipidemia Drugs Market
14. Latin America Global Dyslipidemia Drugs Market
15. MEA Global Dyslipidemia Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Sanofi
- Eli Lilly and Company
- Bristol Myers Squibb Company
- AbbVie Inc.
- GlaxoSmithKline plc
- Daiichi Sankyo Company
- Limited
- Regeneron Pharmaceuticals Inc.
- Mylan N.V. (now Viatris Inc.)
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2024 |
Forecast Period | 2023 - 2034 |
Estimated Market Value ( USD | $ 18.29 Billion |
Forecasted Market Value ( USD | $ 30.98 Billion |
Compound Annual Growth Rate | 4.9% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |